​

Castle Biosciences (CSTL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CSTL Stock Forecast

Castle Biosciences (CSTL) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $40.50, with a high of $45.00 and a low of $36.00. This represents a 47.33% increase from the last price of $27.49.

$15 $21 $27 $33 $39 $45 High: $45 Avg: $40.5 Low: $36 Last Closed Price: $27.49

CSTL Stock Rating

Castle Biosciences stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

CSTL Forecast vs Benchmarks

TypeNameUpside
StockCastle Biosciences47.33%
SectorHealthcare Stocks 25.20%
IndustryDiagnostics & Research Stocks16.01%

Price Target Trends

1M3M12M
# Anlaysts-36
Avg Price Target-$40.00$39.50
Last Closing Price$27.49$27.49$27.49
Upside/Downside-45.51%43.69%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2518---9
Dec, 2418---9
Nov, 2458---13
Oct, 2458---13
Sep, 2458---13
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 05, 2024Sung Ji NamBTIG$45.00$31.1544.46%63.70%
Nov 05, 2024Catherine SchulteRobert W. Baird$39.00$32.8018.90%41.87%
Nov 05, 2024Paul KnightKeyBanc$36.00$32.809.76%30.96%
Oct 29, 2024Kyle MiksonCanaccord Genuity$42.00$32.4029.63%52.78%
Oct 14, 2024Sung Ji NamBTIG$40.00$31.3127.75%45.51%
Aug 06, 2024Sung Ji NamBTIG$35.00$26.2433.38%27.32%
Nov 04, 2022Catherine Schulte AnalystRobert W. Baird$41.00$24.7265.86%49.15%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Nov 05, 2024KeyBancOverweightOverweighthold
Oct 29, 2024StephensBuyBuyhold
Oct 29, 2024Canaccord GenuityBuyBuyhold
Oct 14, 2024BTIGBuyBuyhold
Aug 06, 2024BTIGBuyBuyhold
May 03, 2024Lake StreetBuyBuyhold
Jun 15, 2023BTIGBuyBuyhold
Jun 06, 2023Canaccord GenuityBuyBuyhold
Jan 05, 2023ScotiabankSector Outperforminitialise

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.54$-1.24$-2.58$-2.14-----
Avg Forecast$-0.41$-1.46$-2.72$-2.60$0.39$-1.79$-1.38$-1.22$-0.18
High Forecast$-0.42$-1.51$-2.84$-2.86$0.35$-2.35$-2.54$-2.29$-0.19
Low Forecast$-0.39$-1.40$-2.65$-2.34$0.42$-1.22$-0.40$-0.28$-0.17
Surprise %31.71%-15.07%-5.15%-17.69%-----

Revenue Forecast

$50M $120M $190M $260M $330M $400M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$62.65M$94.08M$137.04M$219.79M-----
Avg Forecast$61.11M$92.78M$135.89M$209.95M$327.49M$274.08M$304.02M$325.14M$367.70M
High Forecast$59.36M$90.12M$132.96M$204.83M$318.47M$266.53M$298.94M$325.14M$357.57M
Low Forecast$62.73M$95.23M$140.49M$215.07M$345.82M$289.42M$309.11M$325.14M$388.28M
Surprise %2.52%1.41%0.84%4.69%-----

Net Income Forecast

$-70M $-53M $-36M $-19M $-2M $15M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-10.28M$-31.29M$-67.14M$-57.47M-----
Avg Forecast$-10.87M$-30.90M$-45.27M$-57.47M$10.37M$-50.49M$-35.73M$-21.80M$-4.69M
High Forecast$-11.25M$-37.07M$-54.32M$-68.96M$9.42M$-63.08M$-68.20M$-61.38M$-5.03M
Low Forecast$-10.47M$-24.72M$-36.21M$-45.97M$11.31M$-32.66M$-10.78M$-7.50M$-4.52M
Surprise %-5.41%1.28%48.31%------

CSTL Forecast FAQ

Is Castle Biosciences stock a buy?

Castle Biosciences stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Castle Biosciences is a favorable investment for most analysts.

What is Castle Biosciences's price target?

Castle Biosciences's price target, set by 4 Wall Street analysts, averages $40.5 over the next 12 months. The price target range spans from $36 at the low end to $45 at the high end, suggesting a potential 47.33% change from the previous close price of $27.49.

How does Castle Biosciences stock forecast compare to the average forecast of its sector, industry, and investment themes?

Castle Biosciences stock forecast shows a 47.33% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the diagnostics & research stocks industry (16.01%).

What is the breakdown of analyst ratings for Castle Biosciences over the past three months?

  • January 2025: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 38.46% Strong Buy, 61.54% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Castle Biosciences’s EPS forecast?

Castle Biosciences's average annual EPS forecast for its fiscal year ending in December is 0.39 for 2024, a -118.22% decrease from the reported $-2.14 in 2023. The prediction for 2025 is $-1.79, $-1.38 for 2026, $-1.22 for 2027, and $-0.18 for 2028.

What is Castle Biosciences’s revenue forecast?

Castle Biosciences's average annual revenue forecast for its fiscal year ending in December is $327.49M for 2024, a 49.00% increase from the reported $219.79M in 2023. The forecast for 2025 is $274.08M, $304.02M for 2026, $325.14M for 2027, and $367.7M for 2028.

What is Castle Biosciences’s net income forecast?

For its fiscal year ending in December, Castle Biosciences's average annual net income forecast is $10.37M for 2024, reflecting a -118.04% decrease from the reported $-57.466M in 2023. The projection for 2025 is $-50.486M, $-35.725M for 2026, $-21.8M for 2027, and $-4.69M for 2028.